Publication Topic

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. 2020. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. Curr Med Res Opin 36(9):1519–1527; doi: 10.1080/03007995.2020.1801403. PMID: 32715807.

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. 2020. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 28(9):4413–4424; doi: 10.1007/s00520-020-05295-2. PMID: 31919669.

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478; doi: 10.1038/s41375-020-0770-8. PMID: 32094465.

Dronin-Fenton D, Dalvi T, Movva N, Pedersen I, Hansen H, Fryzek J, Mellemgaard A, Rasmussen T, et al. PD-L1 expression and survival in stage III unresectable non-small cell lung cancer patients in Denmark. Abstract #2865, European Society for Medical Oncology (ESMO), Virtual, August 2020.

Lafranconi M, Budinsky R, Corey L, Haws L, Klapacz J, Chappell G, Golden R. Exposure to 1,4-dioxane above the metabolic saturation threshold induces a mitogenic key element in the mouse liver cancer mode of action. Abstract #1505. Society of Toxicology 59th Annual Meeting, Virtual, 2020.

Jackson C, Choi J, Khalafallah AM, Price C, Bettegowda C, Lim M, et al. 2020. A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neuro-Oncol 148(3):419–431; doi: 10.1007/s11060-020-03556-y. PMID: 32562247.

Elbeddini A, Hooda N, Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. Am J Case Rep 21:e924058; doi: 10.12659/AJCR.924058. PMID: 32594093.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Jena A, et al. 2020. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ 23(6):581-592; doi: 10.1080/13696998.2020.1730123. PMID: 32063100.

Botros D, Dux H, Price C, Khalafallah AM, Mukherjee D. 2020. Assessing the efficacy of repeat resections in recurrent glioblastoma: A systematic review. Neurosurg Rev 44:1259–1271; doi: 10.1007/s10143-020-01331-1. PMID: 32533385.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. Budget impact of improving adherence to colorectal cancer screening. Abstract PCN148, ISPOR 2020.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. The impact of increasing mt-sDNA use among colorectal cancer screeners in a US employer population. Abstract PCN145, ISPOR 2020.

Cohen S, Reichert H, Kansal AR, Chung KC. Improved efficiency of cancer screening with multi-cancer early detection test. International Society for Pharmacoeconomics and Outcomes Research, Inc. (ISPOR) Virtual Conference, May 2020.

Menon N, Leslie TF, Frankenfeld CL. 2020. Cancer-related diagnostic and treatment capabilities of hospitals in the context of racial residential segregation. Public Health 182(May):95–101; https://doi.org/10.1016/j.puhe.2020.02.004. PMID: 32213360.

Stalbovskaya V, Wasserman E, Fryzek J, Bylsma L, Sirulnik A. NRG1 fusion-driven cancers: A systematic literature review and meta-analysis. Abstract, Annual Meeting of the American Society of Clinical Oncology, May 2020.

Bylsma LC, Dean R, Lowe K, Sangare L, Alexander D, Fryzek J. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics. Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.

Frankenfeld CL, Menon N, Leslie TF. 2020. Racial disparities in colorectal cancer time-to-treatment and survival time for colorectal tumors and diagnosing hospital cancer-related diagnostic and treatment capabilities. Cancer Epidemiol 65(Apr):101684; doi: 10.1016/j.canep.2020.101684. PMID: 32058312.

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of ¹⁸F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362. PMID: 32341772.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al.  Consequences of increasing mt-sDNA utilization among colorectal cancer screening strategies from a payer perspective. American Society of Preventative Oncology 44th Annual ASPO Conference, 2020.

Gadagbui B, Moore J, Parker A, McCready D, Monnot AD, Garnick L, Vincent M, et al. 2020. Derivation of cancer no significant risk levels and screening safety assessment for 2-nitropropane in spray products. J Appl Tox 40(5):691–705; doi: 10.1002/jat.3937. PMID: 32030785.

Bylsma LC, Dean R, Lowe K, Sangare L, Alexander D, Fryzek J. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics. Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.